Satoshi Yamasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Satoshi Yamasaki has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Kawakami
Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences
3 shared publications - Atsumasa Komori
Department of Hepatology, Japan
2 shared publications - Hiromi Ishibashi
Clinical Research Center, Nagasaki Medical Center, Kubara 2-1001-1, Omura, Nagasaki 856-8562, Japan
2 shared publications - Kiyoshi Migita
Clinical Research Center, NHO Nagasaki Medical Center, 2-1001-1 Kubara, Omura 856-8562, Japan
2 shared publications - Minoru Nakamura
Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center
2 shared publications - Taiichiro Miyashita
Department of Rheumatology, Nagasaki Medical Center, Kubara 2-1001-1, Omura, Nagasaki 856-8562, Japan
2 shared publications
Latest Publications
- Open Access
- 18 May 2012
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 14 (3) , R119
Serum amyloid A triggers the mosodium urate -mediated mature interleukin-1β production from human synovial fibroblasts
Background: Monosodium urate (MSU) has been shown to promote inflammasome activation and interleukin-1β (IL-1β) secretion in monocyte/macrophages, but the cellular pathway and nod-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation in synovial tissues, remain elusive. In this study, we investigated the effects of MSU on synovial fibroblasts to elucidate the process of MSU-mediated synovial inflammation. Methods: Human synovial fibroblasts were stimulated with MSU in the presence or absence of serum amyloid A (SAA). The cellular supernatants were analyzed by immunoblotting using anti-IL-1β or anti-caspase-1 antibodies. IL-1β or NLRP3 mRNA expressions were analyzed by real-time PCR or reverse transcription-PCR (RT-PCR) method. Results: Neither SAA nor MSU stimulation resulted in IL-1β or interleukin-1α (IL-1α) secretions and pro-IL-1β processing in synovial fibroblasts. However, in SAA-primed synovial fibroblasts, MSU stimulation resulted in the activation of caspase-1 and production of active IL-1β and IL-1α. The effect of SAA on IL-1β induction was impaired in cells by silencing NLRP3 using siRNA or treating with caspase-1 inhibitor. In addition, SAA induced the secretion of cathepsin B and NLRP3 mRNA expression in synovial fibroblasts. Conclusions: Our data demonstrate that exposure of human synovial fibroblasts to SAA promotes MSU-mediated caspase-1 activation and IL-1β secretion in the absence of microbial stimulation. These findings provide insight into the molecular processes underlying the synovial inflammatory condition of gout.
- 18 May 2012
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 14 (3) , R119
Open AccessSerum amyloid A triggers the mosodium urate -mediated mature interleukin-1β production from human synovial fibroblasts
Background: Monosodium urate (MSU) has been shown to promote inflammasome activation and interleukin-1β (IL-1β) secretion in monocyte/macrophages, but the cellular pathway and nod-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation in synovial tissues, remain elusive. In this study, we investigated the effects of MSU on synovial fibroblasts to elucidate the process of MSU-mediated synovial inflammation. Methods: Human synovial fibroblasts were stimulated with MSU in the presence or absence of serum amyloid A (SAA). The cellular supernatants were analyzed by immunoblotting using anti-IL-1β or anti-caspase-1 antibodies. IL-1β or NLRP3 mRNA expressions were analyzed by real-time PCR or reverse transcription-PCR (RT-PCR) method. Results: Neither SAA nor MSU stimulation resulted in IL-1β or interleukin-1α (IL-1α) secretions and pro-IL-1β processing in synovial fibroblasts. However, in SAA-primed synovial fibroblasts, MSU stimulation resulted in the activation of caspase-1 and production of active IL-1β and IL-1α. The effect of SAA on IL-1β induction was impaired in cells by silencing NLRP3 using siRNA or treating with caspase-1 inhibitor. In addition, SAA induced the secretion of cathepsin B and NLRP3 mRNA expression in synovial fibroblasts. Conclusions: Our data demonstrate that exposure of human synovial fibroblasts to SAA promotes MSU-mediated caspase-1 activation and IL-1β secretion in the absence of microbial stimulation. These findings provide insight into the molecular processes underlying the synovial inflammatory condition of gout.
- Open Access
- 31 August 2011
- Published by Springer Nature in BMC Immunology
- Vol. 12 (1) , 51
Inhibitory effects of the JAK inhibitor CP690,550 on human CD4+ T lymphocyte cytokine production
The new JAK3 inhibitor, CP690,550, has shown efficacy in the treatment of rheumatoid arthritis. The present study was undertaken to assess the effects of CP690,550 on cytokine production and cellular signaling in human CD4+ T cells.
- 31 August 2011
- Published by Springer Nature in BMC Immunology
- Vol. 12 (1) , 51
Open AccessInhibitory effects of the JAK inhibitor CP690,550 on human CD4+ T lymphocyte cytokine production
The new JAK3 inhibitor, CP690,550, has shown efficacy in the treatment of rheumatoid arthritis. The present study was undertaken to assess the effects of CP690,550 on cytokine production and cellular signaling in human CD4+ T cells.
- Open Access
- 1 July 2010
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 11 (1) , 140
Anti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study
To clarify the clinicopathological characteristics of primary Sjögren's syndrome (pSS) with anti-centromere antibody (ACA).
- 1 July 2010
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 11 (1) , 140
Open AccessAnti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study
To clarify the clinicopathological characteristics of primary Sjögren's syndrome (pSS) with anti-centromere antibody (ACA).